Feriha ÇİLLİ, Alper TÜNGER, Meltem Işıkgöz TAŞBAKAN, Sercan ULUSOY, Şöhret AYDEMİR, Hüsnü PULLUKÇU

Susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprim-sulfamethoxazole

Amaç: Özellikle genişlemiş spektrumlu beta-laktamaz (GSBL) üreten Escherichia coli kökenlerinin neden olduğu üriner sistem enfeksiyonlarının tedavisi oldukça güç, mortalite ve morbiditesi de yüksektir. Bu enfeksiyonlar genellikle karbapenemlerle tedavi edilmekte ve yüksek tedavi maliyeti görülmektedir. Çalışmamızda idrar kültürlerinden soyutlanan GSBL üreten E. coli kökenlerinin fosfomisin, siprofloksasin, amikasin ve trimethoprim-sülfametoksazole duyarlılığının araştırılması ve bölgemizdeki üriner sistem enfeksiyonlarından soyutlanan bu kökenlerin genel direnç durumunun belirlenmesi amaçlanmıştır. Yöntem ve Gereç: Ocak 2005-Aralık 2005 tarihleri arasında bakteriyoloji laboratuvarımıza gönderilmiş olan üriner sistem enfeksiyonlarından soyutlanan GSBL üreten kökenler prospektif olarak çalışmaya alınmıştır. GSBL üretimi çift disk sinerji testi ile belirlenmiştir. GSBL üreten suşların antibiyotik duyarlılık testleri "Clinical and Laboratory Standards Institute (CLSI)" kriterlerine göre disk diffüzyon yöntemiyle yapılmıştır. Kontrol kökeni olarak E. coli ATCC 35218 ve ATCC 25922 kullanılmıştır. Nozokomiyal üriner sistem enfeksiyonu tanısı Centers of Disease Control and Prevention kriterlerine gore değerlendirilmiştir. Veriler SPSS 11,0 paket programı kullanılarak değerlendirilmiştir. Bulgular: 2005 yılında laboratuvarımizda soyutlanan 344 GSBL üreten E. coli kökeni (241 nozokomiyal köken, 103 poliklinik hastalarından soyutlanan köken) çalışmaya dahil edilmiştir. Direnç oranlan fosfomisin için % 3,5, siprofloksasin için % 76,5, amikasin için % 11 ve trimetoprimsülfametoksazol için % 74.4'tür. Hastane kaynaklı kökenlerde direnç oranları sırasıyla % 4,1, % 81,3, % 11,2, % 71 iken poliklinik hastalarından soyutlanan kökenlerde % 1,9, % 65, % 10,7, % 82,5'tur. Siprofloksasin ve trimethoprim-sülfametoksazol için iki grup arasında istatistiksel olarak fark vardır. Sonuç: Ülkemizdeki antibiyotik direnç oranlarının yüksek olması nedeniyle, fosfomisin ve amikasinin GSBL üreten E. colfnin neden olduğu komplike olmayan üriner sistem enfeksiyonlarının tedavisinde ilk seçenekler arasında olduğunu düşünmekteyiz.

İdrar kültürlerinde soyutlanan genişlemiş spektrumlu beta-laktamaz üreten Escherichia coli kökenlerinin fosfomisin, siprofloksasin, amikasin ve trimetoprim-sulfametoksazol'e duyarlılıkları

Aim: Urinary tract infections (UTIs) caused in particular by extended-spectrum beta-lactamase (ESBL)- producing Escherichia coli strains are related with high morbidity and mortality, and treatment is quite difficult. These infections generally are treated by carbapenems, and their costs are high. We aimed in this study to investigate the susceptibilities of ESBL-producing E. coli strains isolated from urine cultures to fosfomycin, ciprofloxacin, amikacin and trimethoprim-sulfamethoxazole and to determine the general resistance profile in our region of these strains isolated from UTIs. Materials and Methods: Between January 2005-December 2005, ESBL-producing E. coli strains isolated from urine samples sent from various outpatient and inpatient clinics to the Bacteriology Laboratory of the Department of Microbiology and Clinical Microbiology were included prospectively in the study. ESBL production was detected using the double disk synergy test. Antibiotic susceptibility testing was performed for ESBL-producing isolates by disk diffusion test according to Clinical and Laboratory Standards Institute (CLSI) criteria. Escherichia coli ATCC 35218 and ATCC 25922 were used as control strains. The diagnosis of nosocomial UTIs was established according to the Centers for Disease Control and Prevention criteria. The data were assessed using the SPSS 11.0 packet program. Results: A total of 344 ESBL-producing E. coli isolates (241 nosocomial isolates; 103 outpatient isolates) were included in the study. The rates of resistance were 3.5% for fosfomycin, 76.5% for ciprofloxacin, 11% for amikacin, and 74.4%' for trimethoprim-sulfamethoxazole. While resistance rates of nosocomial strains were 4.1%, 81.3%, 11.2%, and 71%, respectively, resistance rates of the strains isolated from outpatients were 1.9%, 65%, 10.7%, and 82.5%, respectively. There were statistically significant differences between the two groups for ciprofloxacin and trimethoprim-sulfamethoxazole. Conclusions: Because of the high antibiotic resistance rates in our country, we think that fosfomycin and amikacin may have priority in the treatment of non-complicated UTIs caused by ESBL-producing E. coli strains due to ease of use and high concentration in the urine.

PDF

___

1. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, editors. Principle and Practice of Infectious Disease, 6th ed. Philadelphia: Churchill Livingstone; 2000. pp. 773-800.
2. Rahal JJ. Extended-spectrum beta-lactamases: how big is the problem? Clin Microbiol Infect 2000; 6(Suppl 2): 2-6.
3. Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CT-M-type beta-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000; 14: 137-42
4. Bouchillon SK, Johnson BM, Hoban DJ, Johnson JL, Dowzicky MJ, Wu DH et al. Determining incidence of extended spectrum Blactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS Study 2001 - 2002. Int J Antimicrob Agents 2004; 24: 119-24.
5. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-33.
6. Clinical and Laboratory Standards Institute/NCCLS: Performance Standards for Antimicrobial Susceptibility Testing, 15. Informational Supplement, CLSI/NCCLS, M100-S15, Wayne, PA;2005.
7. Sturenburg E, Mark D. Extended spectrum beta lactamases: implications for clinical microbiology laboratory therapy and infection control. J Infect 2003; 47: 273-95.
8. Zarakolu P, Hascelik G, Unal S. Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000- 2004). Mikrobiyol Bült 2006; 40: 147-54.
9. Çetin M, Ocak S, Gorur S, Avunduk G. Uropathogens in patients with symptomatic urinary infection and antibiotic sensitivity of Escherichia coli isolates. ANKEM Derg 2006; 20: 169-72.
10. Guducuoglu H, Baykal S, Izci H, Berktas M. Antimicrobial resistance of Escherichia coli and Klebsiella pneumoniae strains that produce extended spectrum beta-lactamase. ANKEM Derg 2007:21:155-60.
11. Pullukcu H, Tasbakan MI, Aydemir S, Sipahi OR, Turhan A, Ozinel MA et al. The bacteria isolated from urine cultures and their invitro antibiotic susceptibility. ANKEM Dergisi 2006; 20: 26-30.
12. Tolun V, Kucukbasmacı O, Akbulut DT, Çatal C, Kucuker MA, Ang 0. Relationship between ciprofloxacin resistance and extendedspectrum (3-lactamases production in Escherichia coli and Klebsiella pneumoniae strains. Clin Microbiol Infect 2004; 10: 72-5.
13. Mumcuoglu I, Gunduz T, Baydur H. Investigation of extendedspectrum beta-lactamase production and antimicrobial resistance in Escherichia, Klebsiella and Proteus strains. ANKEM Derg 2004; 18:9-11.
14. Kibar F, Yaman A, Dündar IH. The bacteria isolated from urine cultures and their in-vitro antibiotic susceptibility. Türk Mikrobiyoloji Cemiyeti Dergisi 2004; 34: 162-70.
15. Gunduz T, Mumcuoğlu İ. Antibiotic susceptibility of Escherichia coli strains isolated from urine cultures. Türk Mikrobiyoloji Cemiyeti Dergisi 2004; 34: 157-61.
16. Tasbakan MI, Pullukcu H, Sipahi OR, Turhan A, Arda B, Yamazhan T et al. Antibacterial resistance in microbiological confirmed nosocomial bacteremia related Escherichia coli strains in a tertiary care educational hospital in Turkey. Hastane Infeksiyonlan Dergisi 2006; 10 (Suppl 1): 67.
17. Marchese A, Gualco L, Dabbla E, Scito GC, Schito AM. In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 2003; 22: 53-9.
18. Schito GC, Chezzi C, Nicoletti G, Moreddu M, Arcangeletti MC, Stefani S et al. Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: results of Italian multicentre survey. Infection 1992; 20 (Suppl 4): 291-5.
19. Puerto AS, Fernandez JG, Castillo JDL, Pino MJS, Angulo GP. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 2006; 54: 135-9.
20. Tonkic M, Goic-Barisic I, Punda-Polic V. Prevalence and antimicrobial resistance of extended-spectrum beta-lactamasesproducing Escherichia coli and Klebsiella pneumoniae strains isolated in a university hospital in Split, Croatia. Int Microbiol 2005:8:119-24.
21. Kahlmeter G. The ECO.SENS project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrobial Chemother 2000; 46(S1): 15-22.
22. Ungheri D, Albini E, Belluco G. In-vitro susceptibility of quinoloneresistant clinical isolates of Escherichia coli to fosfomycin trometamol. J Chemother 2002; 14(3): 237-40.
23. Alhambra A, Cuadros JA, Cacho J, Garces JLG, Alos Jl. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrobial Chemother 2004; 53: 1090-4.
24. Hernandez JR, Martinez ML, Canton R, Coque TM, Pascual A, Spanish Group for nosocomial infections (GEIH) (2005). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases in Spain. Antimicrob Agents Chemother 2005; 49 (5): 2122-5.
25. Tasbakan MI, Pullukcu H, Yamazhan T, Arda B, Ulusoy S. Comparison of in-vitro activity of fosfomycin and other antibacterials in Escherichia coli strains isolated from community acquired urinary tract infections. ANKEM Dergisi 2004; 18(4):216-9.
26. Arca AE, Karabiber N. Short communication: comparison of 28. susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics. Mikrobiyol Bul. 2007 Jan; 41: 115-9.
27. Deveci O, Taskin SS, Kaygusuz S, Kilic D, Ağalar C. Fosfomycin 29. susceptibility in Escherichia coli strains caused urinary tract infections (Abstract). Klimik Dergisi 2005; 18: 266.
28.Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18: 211-5.
29.Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended-spectrum beta-lactamase-producing Eschenchia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-5.